LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

2.95 -1.34

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.93

Максимум

3.05

Ключови измерители
By Trading Economics
Приходи	-31M -14M
Продажби	-32M 41M
EPS	-0.22
Марж на печалбата	-34.333
Служители	293
EBITDA	-37M -15M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+114.58% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	81M 203M
Предишно отваряне	4.29
Предишно затваряне	2.95

Настроения в новините

By Acuity

47%

53%

161 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

1.47 / 1.64 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.05.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11.05.2026 г., 23:46 ч. UTC

Пазарно говорене

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on AI Enthusiasm -- Market Talk

11.05.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Rises on Possible Position Adjustments -- Market Talk

11.05.2026 г., 22:37 ч. UTC

Пазарно говорене

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11.05.2026 г., 22:32 ч. UTC

Печалби

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11.05.2026 г., 22:02 ч. UTC

Пазарно говорене

Значими събития в новините

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11.05.2026 г., 21:49 ч. UTC

Печалби

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11.05.2026 г., 21:42 ч. UTC

Пазарно говорене

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11.05.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11.05.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11.05.2026 г., 21:23 ч. UTC

Придобивния, сливания и поглъщания

CSG Systems Sale to NEC Gets CFIUS Clearance

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11.05.2026 г., 21:12 ч. UTC

Печалби

Ovintiv 1Q Loss/Shr $2.35 >OVV

11.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

11.05.2026 г., 20:44 ч. UTC

Печалби

Steris: Board Approves New $1B Shr Repurchase Program >STE

11.05.2026 г., 20:43 ч. UTC

Печалби

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11.05.2026 г., 20:32 ч. UTC

Печалби

CleanSpark 2Q Rev $136.4M >CLSK

11.05.2026 г., 20:30 ч. UTC

Печалби

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Cont Ops EPS $2.24 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Rev $1.6B >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11.05.2026 г., 20:30 ч. UTC

Печалби

Steris 4Q Adj EPS $2.83 >STE

11.05.2026 г., 20:22 ч. UTC

Горещи акции

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11.05.2026 г., 19:37 ч. UTC

Печалби

More Bad News at KKR's Private Credit Fund -- Barrons.com

11.05.2026 г., 19:32 ч. UTC

Пазарно говорене

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

114.58% нагоре

12-месечна прогноза

Среден 6.33 USD 114.58%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

161 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.